- A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis
- Apremilast for RAS
- Clinical Evaluation of Fluid Extract of Chamomilla Tincture for Oral Aphthae
- Curcumin and Nanocurcumin in Oral Aphthous Ulcer
- Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis
- Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome
- Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis
- Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations
- Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis
- Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis
- Hyaluronic Acid in Counteracting Aphthous Stomatitis
- Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis
- Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis
- Prevention of Recurrent Aphthous Stomatitis Using Vitamins
- Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis
- Safety, Galenic Acceptability and Efficacy of GV-328 Lozenges in Children With Oral Aphthosis
- Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study
- Therapeutic Effects of “Ibuprofen, Diphenhydramine and Aluminium MgS” on Recurrent Aphthous Stomatitis
- Tokushima Night Guard for Recurrent Aphthous Stomatitis
- Topical Hyaluronic Acid and Recurrent Aphthous Stomatitis.
Clinical Trials
- A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:
- A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
- A Phase II Study of Umbilical Cord Blood Transplantation
- A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
- A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
- A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient
- Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
- Alemtuzumab and Rituximab in Aplastic Anemia
- Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
- Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
- Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain
- Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
- Aplastic Anemia Epidemiology: Incidence and Case-control
- ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
- Avatrombopag Usage in NSAA
- Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
- Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
- Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
- Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors
- Combination Therapy of Severe Aplastic Anemia
- Comparing Therapies for the Treatment of Severe Aplastic Anemia
- Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia
- Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
- Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
- Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
- Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Drug Etiology of Aplastic Anemia and Related Dyscrasias
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
- Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation
- Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
- Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients
- Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
- Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
- Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia
- Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia
- Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
- Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
- Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data
- Extended Dosing With Eltrombopag for Severe Aplastic Anemia
- Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
- Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
- Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
- Haploidentical Transplantation in Severe Aplastic Anemia
- hATG+CsA vs hATG+CsA+Eltrombopag for SAA
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
- Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
- Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
- Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
- Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
- Investigation of the Cylex® ImmuKnow® Assay
- King’s Invasive Aspergillosis Study II
- Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
- Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.
- Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia
- Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
- Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia
- Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
- Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
- Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
- New York Blood Center National Cord Blood Program
- NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
- Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
- Oral Manifestations of Aplastic Anemia
- Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
- Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients
- Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
- Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
- Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
- Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
- Protection Against Benzene Toxicity
- Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
- Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
- Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy
- Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia
- Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)
- Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)
- Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
- REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
- Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy
- Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
- Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
- Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia
- Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
- Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia
- Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
- Safety Study of Cord Blood Units for Stem Cell Transplants
- Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
- Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
- Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
- Stem Cell Factor Medication for Aplastic Anemia
- Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
- Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
- Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
- Study of AMG531(Romiplostim) in Patients With Aplastic Anemia
- Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)
- Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
- Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
- The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia
- Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
- Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
- Transplants With Unlicensed Preserved Cord Blood
- Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones
- Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
- Umbilical Cord Blood Transplantation From Unrelated Donors
- Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia
- Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
- Unrelated Umbilical Cord Blood (UBC)Transplantation
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:
- A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia
- A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
- A Phase II Study of Umbilical Cord Blood Transplantation
- A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
- A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia
- A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
- A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient
- Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
- Alemtuzumab and Rituximab in Aplastic Anemia
- Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
- Allogeneic Stem Cell Transplantation for Patients With Severe Aplastic Anemia
- Ambispective Observational Study to Evaluate the Incidence and Management of Aplastic Anemia in Spain
- Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia
- Aplastic Anemia Epidemiology: Incidence and Case-control
- ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
- Avatrombopag Usage in NSAA
- Blood Transplantation for Patients With Hematologic Malignancies or Bone Marrow Failure States
- Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
- Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
- Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors
- Combination Therapy of Severe Aplastic Anemia
- Comparing Therapies for the Treatment of Severe Aplastic Anemia
- Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia
- Conditioning Regimens for Patients With Severe Aplastic Anemia Transplanted With Marrow From an Unrelated Donor
- Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
- Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
- Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
- Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
- Drug Etiology of Aplastic Anemia and Related Dyscrasias
- Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)
- Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation
- Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)
- Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients
- Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia
- Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
- Efficacy and Safety of Lower-dose Decitabine in Refractory Aplastic Anemia
- Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia
- Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
- Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
- Etiology of Blood Dyscrasias: Analysis of the International Agranulocytosis and Aplastic Anemia Study Data
- Extended Dosing With Eltrombopag for Severe Aplastic Anemia
- Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
- Flu+CPM+rATG Conditioning Regimes for Unrelated Bone Marrow Transplantation (UBMT)(or Mobilized Peripheral Blood)in Severe Aplastic Anemia (SAA)
- Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
- Haploidentical Transplantation in Severe Aplastic Anemia
- hATG+CsA vs hATG+CsA+Eltrombopag for SAA
- Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia
- Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
- Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
- Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
- Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy
- Improving Immunosuppressive Treatment for Patients With Severe Aplastic Anemia
- Investigation of the Cylex® ImmuKnow® Assay
- King’s Invasive Aspergillosis Study II
- Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia
- Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.
- Mesenchymal Stem Cells in the Treatment of Relapsed/Refractory Severe Acquired Aplastic Anemia
- Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.
- Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia
- Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia
- Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders
- Mycophenolate Mofetil and Cyclosporine to Treat Relapsing Aplastic Anemia
- Neuropsychological Effects of Immunosuppressive Treatment in Subjects With Aplastic Anemia
- New York Blood Center National Cord Blood Program
- NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
- Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia
- Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
- Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders
- Oral Manifestations of Aplastic Anemia
- Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study
- Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients
- Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation
- Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT
- Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
- Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
- Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia
- Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
- Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
- Protection Against Benzene Toxicity
- Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia
- Purine Analog-Based Conditioning in Patients With Severe Aplastic Anemia
- Quantitative MRI of Bone Marrow Fat Fraction in Patients With Trepanobiopsy
- Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia
- Randomized Study In Severe Aplastic Anemia Patients Receiving Atg, Cyclosporin A, With Or Without G-CSF (SAA-G-CSF)
- Reduced Toxicity Fludarabine (Flu) + Cyclophosphamide (CPM) + Rabbit Antithymocyte Globulin (rATG) Conditioning Regimen for Unrelated Donor Transplantation in Severe Aplastic Anemia (SAA)
- Reduced-Intensity Preparative Regimen for Allogeneic Stem Cell Transplantation in Patients With Severe Aplastic Anemia
- REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy
- Retrospective Study of Patients With Severe Aplastic Anemia Who Developed High Risk Clonal Evolution With Chromosome 7Abnormalities After Immunosuppressive Therapy
- Retrospective Study of Patients With Severe Aplastic Anemia Who Relapsed After Immunosuppressive Therapy
- Risk Stratification Directed Conditioning Regimen for Haploidentical HSCT in SAA
- Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
- Safety and Efficacy of Patient’s Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia
- Safety and Efficacy Study of Ex Vivo Immunotherapy for Treatment of Aplastic Anemia
- Safety and Efficacy Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat Severe Aplastic Anemia
- Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
- Safety Study of Cord Blood Units for Stem Cell Transplants
- Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
- Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
- Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
- Stem Cell Factor Medication for Aplastic Anemia
- Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission
- Study of Allogeneic Bone Marrow and T-Cell Depleted, CD34+ Peripheral Blood Stem Cell Transplantation in Patients With Aplastic Anemia
- Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia
- Study of AMG531(Romiplostim) in Patients With Aplastic Anemia
- Study of Fludarabine + Cyclophosphamide + TBI Conditioning Regimen for Double Units Cord Blood Transplantation(CBT)in Severe Aplastic Anemia(SAA)
- Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload
- Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia
- The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia
- Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome
- Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
- Transplants With Unlicensed Preserved Cord Blood
- Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones
- Trial of Two Central Venous Catheter (CVC) Flushing Schemes in Pediatric Hematology and Oncology Patients
- Umbilical Cord Blood Transplantation From Unrelated Donors
- Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia
- Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
- Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
- Unrelated Umbilical Cord Blood (UBC)Transplantation
- Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- Ambulatory Screening for Specific Learning Disabilities (SLD) and Developmental Coordination Disorder (DCD).
- Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)
- Exploring the Impact and Feasibility of a Pathway to Sport and Long-term Participation in Young People
- Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke
- Immersive Virtual Environments and Wearable Haptic Devices in Rehabilitation of Children With Neuromotor Impairments
- Occupational Therapy in Patients With Multiple Sclerosis
- Rehabilitating (Stroke-induced) Apraxia With Direct Current Stimulation
- Scholar Performance and Praxis Assessment in Children With Rolandic Epilepsy
- Trial Using CogWatch for Tea Making Training in Stroke Apraxia and Action Disorganisation Syndrome
- A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC – An Expansion
- A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
- A Study of SmartFlow® Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
- An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.
- Prevalence of High Plasmatic 3OMethyldopa Level in a Specific Population of Patients With a Symptomatology Compatible With AADC Deficiency
- Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
- Athlete’s Heart or Arrhythmogenic Right Ventricular Cardiomyopathy: Contribution of Exercise Cardiovascular Magnetic Resonance (CMR)
- Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD
- Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
- DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia
- Isoproterenol Challenge to Detect Arrhythmogenic Right Ventricular Cardiomyopathy
- Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
- Multidisciplinary Study of Right Ventricular Dysplasia
- National ARVC Data Registry and Bio Bank
- Prolonged Monitoring to Detect Ventricular Arrhythmias in Presymptomatic Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Patients
- South Asian Arrhythmogenic Cardiomyopathy Registry
- The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
- Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients
- Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia
- Evaluation of Homecare Reablement, the Trondheim Model
- Ritalin: Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients
- Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
- Factors Contributing to Increased Left Ventricle Size in Patients With Abnormally Enlarged Hearts
- Genetic Analysis of Familial Hypertrophic Cardiomyopathy
- Hypertrophic Cardiomyopathy Registry, Biobank and Imaging Data Repository
- Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy